Replimune Group, Inc. financial data

Symbol
REPL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 Unicorn Park, Woburn, MA
State of incorporation
DE
Fiscal year end
March 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.16K % -32.6%
Debt-to-equity 28.1 % +65.2%
Return On Equity -53.1 % -42.5%
Return On Assets -41.5 % -30.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.4M shares +15.8%
Common Stock, Shares, Outstanding 68.4M shares +15.8%
Entity Public Float 606M USD +24.4%
Common Stock, Value, Issued 68K USD +15.3%
Weighted Average Number of Shares Outstanding, Basic 78.6M shares +18%
Weighted Average Number of Shares Outstanding, Diluted 78.6M shares +18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 172M USD +8.93%
General and Administrative Expense 59.7M USD +6%
Operating Income (Loss) -232M USD -8.16%
Nonoperating Income (Expense) 19M USD +19.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -213M USD -7.25%
Income Tax Expense (Benefit) 408K USD +41.7%
Net Income (Loss) Attributable to Parent -213M USD -7.3%
Earnings Per Share, Basic -3.05 USD/shares +0.65%
Earnings Per Share, Diluted -3.05 USD/shares +0.65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD +49.3%
Assets, Current 443M USD -12.9%
Property, Plant and Equipment, Net 12.6M USD +49.1%
Operating Lease, Right-of-Use Asset 4.42M USD -9.53%
Assets 498M USD -11.4%
Accounts Payable, Current 8.41M USD +92.7%
Liabilities, Current 43.8M USD +9.94%
Operating Lease, Liability, Noncurrent 3.5M USD -13.6%
Other Liabilities, Noncurrent 786K USD +66.5%
Liabilities 117M USD +20.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.63M USD -33.8%
Retained Earnings (Accumulated Deficit) -808M USD -35.8%
Stockholders' Equity Attributable to Parent 381M USD -18%
Liabilities and Equity 498M USD -11.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.2M USD -1.19%
Net Cash Provided by (Used in) Financing Activities 96.6M USD +8645%
Net Cash Provided by (Used in) Investing Activities 29.8M USD +304%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 68.4M shares +15.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 77.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115M USD +48.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.05M USD +61.1%
Deferred Tax Assets, Valuation Allowance 162M USD +42.1%
Deferred Tax Assets, Gross 173M USD +37.9%
Operating Lease, Liability 4.7M USD -9.42%
Depreciation 700K USD +16.7%
Payments to Acquire Property, Plant, and Equipment 449K USD -58%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -215M USD -9.65%
Lessee, Operating Lease, Liability, to be Paid 6.07M USD -12.6%
Property, Plant and Equipment, Gross 24.1M USD +42.4%
Operating Lease, Liability, Current 1.2M USD +5.36%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.17M USD +1.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.2M USD +5.25%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.37M USD -21.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.11M USD -0.71%
Deferred Tax Assets, Operating Loss Carryforwards 142M USD +51.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 8.67M USD -1.03%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.03M USD -4.3%
Operating Lease, Payments 152K USD -42.2%
Additional Paid in Capital 1.19B USD +12.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 900K USD +28.6%
Share-based Payment Arrangement, Expense 8.65M USD -5.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%